Monoclonal antibodies remain one of the most established biologic modalities. Avid Bioservices supports mAb development and CGMP manufacturing with disciplined control of glycosylation, aggregation, and scalability, within a mammalian cell culture platform designed for seamless transition from early development to commercial supply.
Yes. Validated mammalian cell culture platforms support transition from clinical batches to commercial-scale production using scalable platforms and sound engineering principles.
Stable mammalian cell lines, scalable upstream and purification processes, and robust analytical assays to measure glycosylation, charge variants, and aggregation are essential for consistent mAb production.
Advance Your Monoclonal Antibody (mAb) Program With Confidence
Connect with our team to discuss development timelines, manufacturing strategy, and scalable CGMP production.
